Skip to main content
Triangle logo TriangleGet started

PEP-CMV (NCT05096481)

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma: a one-minute explainerNCT050964811 min

PEP-CMV trial for High Grade Glioma (NCT05096481). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients aged 3–39 with recurrent or refractory medulloblastoma, or newly diagnosed diffuse intrinsic pontine glioma. Both require prior radiation, except medulloblastoma below age four. The high-grade glioma group is closed.

The idea: PEP-CMV targets CMV antigens to direct immune attack. Temozolomide and tetanus-diphtheria preparation precede skin injections, two weeks apart then four-weekly. DIPG enrollment is within six weeks after radiation. Researchers assess progression and survival.

This phase 2 study plans 120 patients. Total includes closed group. Maryam Fouladi leads at Nationwide Children's in Columbus; ten US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.